USRE39609E1 - 8-iso-prostaglandins for glaucoma therapy - Google Patents

8-iso-prostaglandins for glaucoma therapy Download PDF

Info

Publication number
USRE39609E1
USRE39609E1 US10/073,838 US7383802A USRE39609E US RE39609 E1 USRE39609 E1 US RE39609E1 US 7383802 A US7383802 A US 7383802A US RE39609 E USRE39609 E US RE39609E
Authority
US
United States
Prior art keywords
iso
derivative
prostanoid
group
following formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
US10/073,838
Inventor
Steven M. Podos
Thomas W. Mittag
Bernard Becker
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Icahn School of Medicine at Mount Sinai
Original Assignee
Mount Sinai School of Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mount Sinai School of Medicine filed Critical Mount Sinai School of Medicine
Priority to US10/073,838 priority Critical patent/USRE39609E1/en
Application granted granted Critical
Publication of USRE39609E1 publication Critical patent/USRE39609E1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics

Definitions

  • the present invention relates to the use of 8-iso prostaglandins and their derivatives for decreasing intraocular pressure, for example in the treatment of glaucoma. It is based, at least in part, on the discovery that 8-iso prostaglandin E 2 effectively decreased intraocular pressure by a trabecular meshwork outflow mechanism.
  • Glaucoma is a major eye disease which can cause progressive loss of vision leading to blindness.
  • the majority of human glaucomas are associated with increased intraocular pressure (“IOP”) resulting from an imbalance in the rate of secretion of aqueous humor by the ciliary epithelium into the anterior and posterior chambers of the eye and the rate of aqueous humor outflow from these chambers, primarily via the canal of Schlemm.
  • IOP intraocular pressure
  • High IOP is considered the major risk factor for glaucomatous visual impairment resulting from the death of retinal ganglion cells, loss of the nerve fiber layer in the retina, and destruction of the axons of the optic nerve.
  • Current treatments are directed toward reducing intraocular pressure.
  • Glaucoma is typically classified, on the basis of its etiology, as primary or secondary.
  • Primary glaucoma in adults a disorder in which the underlying cause is poorly understood, is associated with increased IOP due to an obstruction of aqueous human outflow.
  • the obstruction may be caused by a blockage located at the angle formed between the iris and the lateral cornea, categorized as either open angle or acute or chronic angle closure.
  • the anterior chamber of the eye appears normal in chronic open angle glaucoma, despite impaired drainage of aqueous humor.
  • the anterior chamber is shallow and the filtration angle is narrowed in chronic angle-closure glaucoma, wherein the trabecular meshwork and the canal of Schlemm may be obstructed by the iris.
  • An acute attack of glaucoma may arise in this context when the pupil dilates, pushing the root of the iris forward to block the angle.
  • Secondary glaucoma is caused by another disorder which functionally interferes with the outflow of aqueous humor or the flow from the posterior to the anterior chamber.
  • Such interference may be caused by inflammation, a tumor, an enlarged cataract, central retinal vein occlusion, trauma, or hemorrhage.
  • beta adrenergic blockers e.g., timolol
  • topical carbonic anhydrase inhibitors e.g., dorzolamide
  • alpha 2 -adrenergic receptor agonists e.g., clonidine derivatives
  • Pilocarpine and epinephrine are clinical agents that also lower IOP in glaucamatous eyes, but these drugs act principally by decreasing the resistance in the trabecular meshwork outflow channels.
  • a third mechanism for lowering IOP in the primate eye is by increasing the outflow of aqueous humor via the uveoscleral route.
  • a prostaglandin derivative belonging to the F2 ⁇ series of prostanoids which acts primarily by this uveoscleral mechanism, has been introduced for glaucoma therapy.
  • This drug, called latanoprost is the isopropyl ester of a compound having the following structure:
  • Prostaglandins which may be used in the treatment of glaucoma are described in U.S. Pat. Nos. 5,476,872 by Garst et al., 4,599,353 by Bito, 5,262,437 by Chan, 5,462,968 by Woodward, 4,132,847 by Kuhla, 5,173,507 by DeSantis et al., 5,578,618 by Stjernschantz et al., 5,208,256 by Ueno, 5,565,492 by DeSantis et al., 5,151,444 by Ueno et al., and PCT Application No. PCT/US93/10853, International Publication No. WO 94/11002 by Woodward.
  • the present invention relates to prostaglandins which are structurally different from latanoprost and other prostaglandins used in the treatment of glaucoma, and that belong to the 8-iso series of prostanoids, for example 8-iso PGE 2 , 8-iso PGE 2 and 8-iso PGF 2 ⁇ .
  • 8-isoPGE 2 lowers IOP primarily by decreasing the resistance to trabecular outflow of aqueous humor from the eye.
  • the present invention relates to the use of 8-iso prostanoids in methods which decrease intraocular pressure (“IOP”) in the eye, for example in the treatment of glaucoma.
  • the 8-iso-prostanoids of the invention have a common structure according to formula I: where either bond W or bond X can be a single or a double bond, Y is either (i) a hydroxyl group having either ⁇ or ⁇ orientation relative to the five-membered ring or (ii) a keto function at carbon 9, and Z is a hydrocarbon group which may be aliphatic (cyclic or non-cyclic), aromatic, or a combination of aliphatic and aromatic at carbon 16.
  • the 8-iso prostanoid is 8-iso prostaglandin E 2 (prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo, (5Z, 8 ⁇ , 11 ⁇ , 13E,15S), having Formula II:
  • the 8-iso prostanoid is 8-iso, 5,6 dihydro prostaglandin E 2 (referred to as 8-iso PGE 1 ), having Formula II:
  • the 8-iso prostanoid is 8-iso PGF 2 ⁇ , (prosta-5,13-dien-1-oic acid, 9, 11, 15-trihydroxy-, (5Z, 8 ⁇ , 9 ⁇ , 11 ⁇ , 13E, 15S)-, having Formula IV:
  • the present invention also provides for derivatives of compounds of Formulas II, III or IV which retain basic Formula I and their use in methods of decreasing intraocular pressure.
  • the present invention relates to the use of 8-iso prostanoids having basic Formula I to decrease intraocular pressure in a subject in need of such treatment.
  • the 8-iso prostanoid may be selected from the group of (i) 8-iso prostaglandin E 2 (prosta-5,13-dien-1-oic acid, 11,15-hydroxy-9-oxo, (5Z, 8 ⁇ , 9 ⁇ , 11 ⁇ , 13E, 15S) (“8-iso PGE 2 ”), having Formula II; (ii) the 5,6 dihydro derivative of 8-iso PGE 2 , having Formula III and referred to as 8-iso PGE 1 ; (iii) prosta-5,13-dien-1-oic acid, 9, 11, 15-trihydroxy-, (5Z, 8 ⁇ , 9 ⁇ , 11 ⁇ , 13E, 15S) (“8-iso PGF 2 ⁇ ”), having Formula IV; and (iv) derivatives of compounds having Formulas II, III or IV which retain basic Formula I
  • the main structural differences between the 8-iso prostanoids of the invention and latanoprost are the following: (i) the side chain substituents on the five-membered rings have the opposite geometric arrangement with respect to the plane of the ring (cis for the 8-iso prostanoids of the invention and trans for latanoprost); (ii) the five-membered ring has a keto or hydroxyl function at position 9 in the 8-iso prostanoids of the invention, whereas there is just a hydroxyl group in the same position in latanoprost; and (iii) the side chains beginning with the sixteenth carbon may have different structures, as, for example, latanoprost containing a terminal methyl phenyl group at this position.
  • 8-iso prostanoid derivatives of the invention contain a five-membered ring and two side chains, and retain distinguishing features (i)-(iii) as set forth in the preceding sentence and in Formula I.
  • such derivatives are esters of compounds having Formula II, III or IV.
  • esterified derivatives of 8-iso PGE 2 may be used according to the invention, and may provide improved penetration into the eye.
  • the present invention provides for a method for decreasing IOP comprising administering a therapeutically effective amount of an 8-iso prostanoid of the invention to a subject in need of such treatment.
  • a method may be used in the treatment of glaucoma in a subject.
  • suitable formulations include for example, and not by way of limitation, a topical solution which is a physiological saline solution, having a pH between about 4.5 and 8 and an appropriate buffer system (e.g., acetate buffers, citrate buffers, phosphate buffers, borate buffers) a neutral pH being preferred.
  • the formulation may further comprise a pharmaceutically acceptable preservative (e.g.
  • the formulation may also comprise a compound which acts as an anti-oxidant (e.g. sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole, butylated hydroxytoluene).
  • a “therapeutically effective amount” of an 8-iso prostanoid of the invention refers to an amount of drug which decreases the IOP by at least about 10 percent, preferably at least about 15 percent, and more preferably at least about 20 percent.
  • the administration of 8-iso prostanoid results in an increase in trabecular outflow facility of at least about 10 percent, preferably at least about 20 percent, and more preferably at least about 30 percent.
  • a topical preparation of 8-iso prostanoid at a concentration of between 0.001 and 1 percent, preferably between 0.05 and 0.2 percent, and more preferably between about 0.05 and 0.1 percent may be used.
  • IOP may be decreased, and/or glaucoma may be treated, using compositions comprising an 8-iso prostanoid of the invention as the sole active agent, or in conjunction with another active agent.
  • an 8-iso prostanoid of the invention as the sole active agent, or in conjunction with another active agent.
  • combination of 8-iso prostanoid and another drug used to treat elevated intraocular pressure including but not limited to another prostaglandin derivative (including, but not limited to, latanoprost), pilocarpine, epinephrine, a beta adrenergic agent (e.g., timolol), a carbonic anhydrase inhibitor (e.g., dorzolamide), or an alpha 2 -adrenergic receptor agonist (e.g., a clonidine derivative), may be used.
  • another prostaglandin derivative including, but not limited to, latanoprost
  • pilocarpine epinephrine
  • 8-isoPGE 2 reduced IOP (p ⁇ 0.005) up to 2 hrs or 5 hrs following administration of the 0.05% or 0.1% concentration, respectively.
  • the maximum reduction in IOP was 4.6 ⁇ 0.8 (mean ⁇ SEM)mm Hg (0.05%) and 6.6 ⁇ 0.8 mm Hg (0.1%), as compared to baseline measurements.
  • the IOP was lower (p ⁇ 0.01) in the treated eyes of 6 N monkeys for 4 hrs, with a maximum difference of 3.2 ⁇ 0.2 mmHg, as compared to the fellow contralateral control eyes.
  • the pupil size was smaller (p ⁇ 0.01) for 4 hrs, up to 1.0 ⁇ 0.2 mm.
  • C Compared with vehicle-treated contralateral control eyes, C was greater (p ⁇ 0.005) by 48% at 2 hr after a single dose of 0.1% 8-iso PGE 2 . F was unchanged (p ⁇ 0.10) over a period of 4 hrs after drug administration. Mild eyelid edema, conjunctival edema, hyperemia, and discharge appeared in some eyes treated with the 0.1% concentration.
  • Table 1A shows that 8-iso PGE 2 administrated to the normal monkey eye lowers IOP significantly by 20.3% and increases outflow facility by 43.1%, an amount sufficient to account for the fall of IOP.
  • Table 1B latanoprost in the normal monkey eye also lowers IOP significantly (by 10.8%), but the drug has not significant effect on outflow facility.
  • the lack of a major effect on outflow facility of latanoprost in the primate eye is in agreement with studies in the literature by other investigators.
  • Intraocular Pressure Outflow Facility Mean ⁇ SEM Mean ⁇ SEM mmHg ⁇ l/min/mmHg Treated eyes (drug) 13.2 ⁇ 0.7* 0.76 ⁇ 0.08 Baseline 14.8 ⁇ 0.7 0.62 ⁇ 0.07 Control eyes (vehicle) 15.0 ⁇ 0.8 0.60 ⁇ 0.07 Baseline** 15.7 ⁇ 0.3 0.73 ⁇ 0.08 *Significantly different as compared with either baseline values or vehicle-treated eyes (two-tailed paired t-test, p. ⁇ 0.05. **Baseline measurements made in the same monkeys at the same time one day prior to drug treatments
  • Table 2 shows the effect of 8-iso PGE 2 on IOP and outflow facility in glaucomatous monkey eyes. Because of the individual variability in laser-induced glaucomatous monkey eyes, the IOP and facility measurements are expressed in the table as ratios (value of the drug-treated eye+the value of the vehicle-treated eye). The ratios were calculated from the values of the same glaucomatous monkey eye determined immediately prior to administration of the drug or the vehicle (time 0 hrs.), and the values at 2 hours after administration of the drug or vehicle.
  • IOP was measured one hour before and at intervals up to six hours after a single dose of 8-iso PGE, (the 13, 14 dihydro derivative of 8-iso PGE 2 ), 8-iso PGE 2 , or 8-iso PGF 2 ⁇ in laser-induced glaucomatous eyes in cynomolgus monkeys (wherein only one eye is rendered glaucomatous and the other serves as a control).
  • Intraocular Pressure (treated - baseline) (mean mm Hg ⁇ SEM) iso PG, 0.1% n 1 hr 2 hr 4 hr 6 hr 8-iso PGE 1 4 ⁇ 3.3 ⁇ 1.3 ⁇ 5.3 ⁇ 0.8* ⁇ 2.3 ⁇ 0.5* ⁇ 1.3 ⁇ 0.9 8-iso PGE 2 8 ⁇ 4.5 ⁇ 0.9** ⁇ 6.6 ⁇ 0.8** ⁇ 2.9 ⁇ 0.6** ⁇ 1.2 ⁇ 1.2 8-iso PGE 2 ⁇ 4 ⁇ 3.3 ⁇ 0.8* ⁇ 1.8 ⁇ 1.1 ⁇ 0.8 ⁇ 1.7 0.3 ⁇ 0.5 *p ⁇ 0.05 **p ⁇ 0.005

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to the use of 8-iso prostaglandins and their derivatives for decreasing intraocular pressure, for example in the treatment of glaucoma It is based, at least in part, on the discovery that 8-iso prostaglandin E2 effectively decreased intraocular pressure by a trabecular meshwork outflow mechanism.

Description

This application is a continuation of U.S. Ser. No. 08/853,803 filed May 9, 1997 now abandoned.
INTRODUCTION
The present invention relates to the use of 8-iso prostaglandins and their derivatives for decreasing intraocular pressure, for example in the treatment of glaucoma. It is based, at least in part, on the discovery that 8-iso prostaglandin E2 effectively decreased intraocular pressure by a trabecular meshwork outflow mechanism.
BACKGROUND OF THE INVENTION
Glaucoma is a major eye disease which can cause progressive loss of vision leading to blindness. The majority of human glaucomas are associated with increased intraocular pressure (“IOP”) resulting from an imbalance in the rate of secretion of aqueous humor by the ciliary epithelium into the anterior and posterior chambers of the eye and the rate of aqueous humor outflow from these chambers, primarily via the canal of Schlemm. High IOP is considered the major risk factor for glaucomatous visual impairment resulting from the death of retinal ganglion cells, loss of the nerve fiber layer in the retina, and destruction of the axons of the optic nerve. Current treatments are directed toward reducing intraocular pressure.
Glaucoma is typically classified, on the basis of its etiology, as primary or secondary. Primary glaucoma in adults, a disorder in which the underlying cause is poorly understood, is associated with increased IOP due to an obstruction of aqueous human outflow. The obstruction may be caused by a blockage located at the angle formed between the iris and the lateral cornea, categorized as either open angle or acute or chronic angle closure. The anterior chamber of the eye appears normal in chronic open angle glaucoma, despite impaired drainage of aqueous humor. In contrast, the anterior chamber is shallow and the filtration angle is narrowed in chronic angle-closure glaucoma, wherein the trabecular meshwork and the canal of Schlemm may be obstructed by the iris. An acute attack of glaucoma may arise in this context when the pupil dilates, pushing the root of the iris forward to block the angle.
Secondary glaucoma is caused by another disorder which functionally interferes with the outflow of aqueous humor or the flow from the posterior to the anterior chamber. Such interference may be caused by inflammation, a tumor, an enlarged cataract, central retinal vein occlusion, trauma, or hemorrhage.
Several classes of drugs acting by different mechanisms are used as topically administered ocular therapy to lower IOP. These include beta adrenergic blockers (e.g., timolol), topical carbonic anhydrase inhibitors (e.g., dorzolamide), and alpha2-adrenergic receptor agonists (e.g., clonidine derivatives), all of which act primarily by decreasing the formation of aqueous humor within the eye. Pilocarpine and epinephrine are clinical agents that also lower IOP in glaucamatous eyes, but these drugs act principally by decreasing the resistance in the trabecular meshwork outflow channels. A third mechanism for lowering IOP in the primate eye is by increasing the outflow of aqueous humor via the uveoscleral route. Recently, a prostaglandin derivative belonging to the F2α series of prostanoids, which acts primarily by this uveoscleral mechanism, has been introduced for glaucoma therapy. This drug, called latanoprost, is the isopropyl ester of a compound having the following structure:
Figure USRE039609-20070501-C00001
Prostaglandins which may be used in the treatment of glaucoma are described in U.S. Pat. Nos. 5,476,872 by Garst et al., 4,599,353 by Bito, 5,262,437 by Chan, 5,462,968 by Woodward, 4,132,847 by Kuhla, 5,173,507 by DeSantis et al., 5,578,618 by Stjernschantz et al., 5,208,256 by Ueno, 5,565,492 by DeSantis et al., 5,151,444 by Ueno et al., and PCT Application No. PCT/US93/10853, International Publication No. WO 94/11002 by Woodward.
The present invention relates to prostaglandins which are structurally different from latanoprost and other prostaglandins used in the treatment of glaucoma, and that belong to the 8-iso series of prostanoids, for example 8-iso PGE2, 8-iso PGE2 and 8-iso PGF2α. In contrast to latanoprost, 8-isoPGE2 lowers IOP primarily by decreasing the resistance to trabecular outflow of aqueous humor from the eye.
SUMMARY OF THE INVENTION
The present invention relates to the use of 8-iso prostanoids in methods which decrease intraocular pressure (“IOP”) in the eye, for example in the treatment of glaucoma. The 8-iso-prostanoids of the invention have a common structure according to formula I:
Figure USRE039609-20070501-C00002
where either bond W or bond X can be a single or a double bond, Y is either (i) a hydroxyl group having either α or β orientation relative to the five-membered ring or (ii) a keto function at carbon 9, and Z is a hydrocarbon group which may be aliphatic (cyclic or non-cyclic), aromatic, or a combination of aliphatic and aromatic at carbon 16.
In a first nonlimiting embodiment of the invention, the 8-iso prostanoid is 8-iso prostaglandin E2 (prosta-5,13-dien-1-oic acid, 11,15-dihydroxy-9-oxo, (5Z, 8β, 11α, 13E,15S), having Formula II:
Figure USRE039609-20070501-C00003
In a second nonlimiting embodiment of the invention, the 8-iso prostanoid is 8-iso, 5,6 dihydro prostaglandin E2 (referred to as 8-iso PGE1), having Formula II:
Figure USRE039609-20070501-C00004
In a third nonlimiting embodiment of the invention, the 8-iso prostanoid is 8-iso PGF2α, (prosta-5,13-dien-1-oic acid, 9, 11, 15-trihydroxy-, (5Z, 8β, 9α, 11α, 13E, 15S)-, having Formula IV:
Figure USRE039609-20070501-C00005
The present invention also provides for derivatives of compounds of Formulas II, III or IV which retain basic Formula I and their use in methods of decreasing intraocular pressure.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to the use of 8-iso prostanoids having basic Formula I to decrease intraocular pressure in a subject in need of such treatment. In specific nonlimiting embodiments of the invention, the 8-iso prostanoid may be selected from the group of (i) 8-iso prostaglandin E2 (prosta-5,13-dien-1-oic acid, 11,15-hydroxy-9-oxo, (5Z, 8β, 9α, 11α, 13E, 15S) (“8-iso PGE2”), having Formula II; (ii) the 5,6 dihydro derivative of 8-iso PGE2, having Formula III and referred to as 8-iso PGE1; (iii) prosta-5,13-dien-1-oic acid, 9, 11, 15-trihydroxy-, (5Z, 8β, 9α, 11α, 13E, 15S) (“8-iso PGF2 α”), having Formula IV; and (iv) derivatives of compounds having Formulas II, III or IV which retain basic Formula I and which, when administered to the eye of a subject having increased intraocular pressures, will decrease intraocular pressure by at least 10 percent.
The main structural differences between the 8-iso prostanoids of the invention and latanoprost are the following: (i) the side chain substituents on the five-membered rings have the opposite geometric arrangement with respect to the plane of the ring (cis for the 8-iso prostanoids of the invention and trans for latanoprost); (ii) the five-membered ring has a keto or hydroxyl function at position 9 in the 8-iso prostanoids of the invention, whereas there is just a hydroxyl group in the same position in latanoprost; and (iii) the side chains beginning with the sixteenth carbon may have different structures, as, for example, latanoprost containing a terminal methyl phenyl group at this position. 8-iso prostanoid derivatives of the invention contain a five-membered ring and two side chains, and retain distinguishing features (i)-(iii) as set forth in the preceding sentence and in Formula I. In preferred embodiments, such derivatives are esters of compounds having Formula II, III or IV. For example, esterified derivatives of 8-iso PGE2 may be used according to the invention, and may provide improved penetration into the eye.
The mechanism of action by which 8-iso PGE2 lowers IO has been found to be different from that of latanoprost in experiments done in primates, in that 8-iso PGE2 has been found to increase trabecular outflow facility by decreasing resistance to outflow of aqueous humor. This is an advantage in that the trabecular meshwork is the primary locus of the pathology causing increased IOP in primary open angle glaucoma.
Accordingly, the present invention provides for a method for decreasing IOP comprising administering a therapeutically effective amount of an 8-iso prostanoid of the invention to a subject in need of such treatment. Such a method may be used in the treatment of glaucoma in a subject. Suitable formulations include for example, and not by way of limitation, a topical solution which is a physiological saline solution, having a pH between about 4.5 and 8 and an appropriate buffer system (e.g., acetate buffers, citrate buffers, phosphate buffers, borate buffers) a neutral pH being preferred. The formulation may further comprise a pharmaceutically acceptable preservative (e.g. benzalkonium chloride, thimerosol, chlorobutanol), stabilizer and/or surfactant (e.g. Tween 80). The formulation may also comprise a compound which acts as an anti-oxidant (e.g. sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole, butylated hydroxytoluene). A “therapeutically effective amount” of an 8-iso prostanoid of the invention refers to an amount of drug which decreases the IOP by at least about 10 percent, preferably at least about 15 percent, and more preferably at least about 20 percent. In particular embodiments of the invention, the administration of 8-iso prostanoid results in an increase in trabecular outflow facility of at least about 10 percent, preferably at least about 20 percent, and more preferably at least about 30 percent. In nonlimiting embodiments of invention, a topical preparation of 8-iso prostanoid at a concentration of between 0.001 and 1 percent, preferably between 0.05 and 0.2 percent, and more preferably between about 0.05 and 0.1 percent may be used.
According to the invention, IOP may be decreased, and/or glaucoma may be treated, using compositions comprising an 8-iso prostanoid of the invention as the sole active agent, or in conjunction with another active agent. For example, combination of 8-iso prostanoid and another drug used to treat elevated intraocular pressure, including but not limited to another prostaglandin derivative (including, but not limited to, latanoprost), pilocarpine, epinephrine, a beta adrenergic agent (e.g., timolol), a carbonic anhydrase inhibitor (e.g., dorzolamide), or an alpha2-adrenergic receptor agonist (e.g., a clonidine derivative), may be used.
EXAMPLE 1
Experiments were performed to evaluate the effects of single dose administration of 8-iso PGE2 an IOP in normal (“N”) and glaucomatous (“G”) monkey eyes, and to determine the mechanism by which 8-iso PGE2 alters IOP in N monkey eyes, when applied topically. A single 25 μl dose study was performed in 6 N and 8 G monkeys. IOP and pupil sizes were measured before and at 0 hr, 0.5 hr and then hourly for a total of 6 hrs after 0.05% or 0.1% drug concentrations were administered. Tonographic outflow facility (“C”) and fluorophotometric aqueous humor flow (F) were determined in 6 N monkeys before and after unilateral application of 25 μl of 0.1% 8-iso PGE2. In 8 G monkey eyes, 8-isoPGE2 reduced IOP (p<0.005) up to 2 hrs or 5 hrs following administration of the 0.05% or 0.1% concentration, respectively. The maximum reduction in IOP was 4.6±0.8 (mean±SEM)mm Hg (0.05%) and 6.6±0.8 mm Hg (0.1%), as compared to baseline measurements. After topical application of 8-iso PGE2 the IOP was lower (p<0.01) in the treated eyes of 6 N monkeys for 4 hrs, with a maximum difference of 3.2±0.2 mmHg, as compared to the fellow contralateral control eyes. The pupil size was smaller (p<0.01) for 4 hrs, up to 1.0±0.2 mm. Compared with vehicle-treated contralateral control eyes, C was greater (p<0.005) by 48% at 2 hr after a single dose of 0.1% 8-iso PGE2. F was unchanged (p<0.10) over a period of 4 hrs after drug administration. Mild eyelid edema, conjunctival edema, hyperemia, and discharge appeared in some eyes treated with the 0.1% concentration.
Table 1A shows that 8-iso PGE2 administrated to the normal monkey eye lowers IOP significantly by 20.3% and increases outflow facility by 43.1%, an amount sufficient to account for the fall of IOP. By contrast, in Table 1B latanoprost in the normal monkey eye also lowers IOP significantly (by 10.8%), but the drug has not significant effect on outflow facility. The lack of a major effect on outflow facility of latanoprost in the primate eye is in agreement with studies in the literature by other investigators.
TABLE 1
A. Effect of 0.1% 8-isoPGE2 on Outflow Facility in 6 Normal
Monkeys (2 hours after treatment)
Intraocular Pressure Outflow Facility
Mean ± SEM Mean ± SEM
mmHg μl/ml/mmHg
Treated eyes (drug) 13.0 ± 0.7* 0.83 ± 0.10*
Baseline 16.3 ± 1.1 0.58 ± 0.03
Control eyes (vehicle) 15.7 ± 0.5 0.56 ± 0.06
Baseline** 15.7 ± 0.6 0.51 ± 0.04
B. Effect of 0.005% latanoprost on Outflow Facility in 6 Normal
Monkeys (1 hour after treatment)
Intraocular Pressure Outflow Facility
Mean ± SEM Mean ± SEM
mmHg μl/min/mmHg
Treated eyes (drug) 13.2 ± 0.7* 0.76 ± 0.08
Baseline 14.8 ± 0.7 0.62 ± 0.07
Control eyes (vehicle) 15.0 ± 0.8 0.60 ± 0.07
Baseline** 15.7 ± 0.3 0.73 ± 0.08
*Significantly different as compared with either baseline values or vehicle-treated eyes (two-tailed paired t-test, p. < 0.05.
**Baseline measurements made in the same monkeys at the same time one day prior to drug treatments
Table 2 shows the effect of 8-iso PGE2 on IOP and outflow facility in glaucomatous monkey eyes. Because of the individual variability in laser-induced glaucomatous monkey eyes, the IOP and facility measurements are expressed in the table as ratios (value of the drug-treated eye+the value of the vehicle-treated eye). The ratios were calculated from the values of the same glaucomatous monkey eye determined immediately prior to administration of the drug or the vehicle (time 0 hrs.), and the values at 2 hours after administration of the drug or vehicle. The data in Table 2 show that in the primate, administration of 8-iso PGE2 to glaucomatous eyes significantly lowers IOP (by 13.8%) and significantly increases outflow facility (by 38.8%), which is of sufficient magnitude to account for the fall in IOP. Thus the mechanism of lowering IOP by 8-iso PGE2 in both normal and glaucomatous eyes is primarily due to an increase in aqueous humor trabecular outflow.
TABLE 2
Effect of 0.1% 8-iso PGE2 on IOP Outflow Facility Responses
in 8 Glaucomatous Monkey Eyes (Unilateral)
Intraocular Pressure Outflow facility
(drug-treated/ (drug-treated/
vehicle-treated) vehicle treated)
Time 0 hr 2 hr 0 hr 2 hr
Response Ratio (±SEM) 0.976 ± 0.843* ± 1.041 ± 1.445** ±
0.002 0.0498 0.0498 0.161
% Change by drug — 13.8% — 38.8%
decrease decrease
Significantly different as compared to 0 hr, paired t-test, p < 0.01*, <0.10**
EXAMPLE II
IOP was measured one hour before and at intervals up to six hours after a single dose of 8-iso PGE, (the 13, 14 dihydro derivative of 8-iso PGE2), 8-iso PGE2, or 8-iso PGF2α in laser-induced glaucomatous eyes in cynomolgus monkeys (wherein only one eye is rendered glaucomatous and the other serves as a control). Following one day of baseline IOP measurement, a single 25 μl dose of either (i) 0.1 percent 8-iso PGE1, or (ii) 0.1 percent 8-iso PGE2, or (iii) 0.1 percent 8-iso PGF2α, was topically applied to the glaucomatous eye in groups of 4 or 8 monkeys. It was found that 8-iso PGE1 (0.1 percent) reduced IOP (p<0.05) for up to four hours in glaucomatous monkey eyes (n=4). The maximum reduction in IOP was 5.3±0.8 (mean SEM) mm Hg at 2 hours after dosing 8-iso PGE2 (0.1 percent) reduced IOP (p<0.05) for 5 hours with a maximum reduction in IOP of 6.6±0.8 mm Hg at 2 hours after dosing (n=8). After 0.1 percent 8-iso PGF2α, a significant (p<0.05) reduction in IOP occurred only at 1 hour with the maximum reduction in IOP of 3.3±0.9 mm Hg (n=4). The results are shown in Table 3. Based on these studies, of the compounds tested, 8-iso PGE2 appears to have the greatest and 8-iso PGF2α, the least activity in decreasing IOP in glaucomatous monkey eyes.
TABLE 3
Intraocular Pressure (treated - baseline) (mean mm Hg ± SEM)
iso PG, 0.1% n 1 hr 2 hr 4 hr 6 hr
8-iso PGE1 4 −3.3 ± 1.3 −5.3 ± 0.8* −2.3 ± 0.5* −1.3 ± 0.9
8-iso PGE2 8 −4.5 ± 0.9** −6.6 ± 0.8** −2.9 ± 0.6** −1.2 ± 1.2
8-iso PGE2α 4 −3.3 ± 0.8* −1.8 ± 1.1 −0.8 ± 1.7   0.3 ± 0.5
*p < 0.05
**p < 0.005
Various publications are cited herein, the contents of which are hereby incorporated by reference in their entireties.

Claims (24)

1. A method for decreasing intraocular pressure comprising administering a therapeutically effective amount of an 8-iso prostanoid having the following Formula I:
Figure USRE039609-20070501-C00006
where bond W is selected from the group consisting of a single covalent bond and a double covalent bond, bond X is selected from the group consisting of a single covalent bond and a double bond, substituent Y is selected from the group consisting of a hydroxyl group having either α or β orientation relative to the five-membered ring and a keto function, and substituent Z is a hydrocarbon group selected from the group of aliphatic, aromatic, or a combination of aliphatic and aromatic hydrocarbon, to a patient in need of such treatment.
2. The method of claim 1 wherein the 8-isoprostanoid is administered topically.
3. The method of claim 2 wherein the 8-iso prostanoid is administered as a composition comprising between 0.005 to 1 percent 8-iso prostanoid.
4. The method of claim 1, wherein the 8-iso prostanoid is selected from the group consisting of a compound having the following Formula II
Figure USRE039609-20070501-C00007
or a derivative thereof.
5. The method of claim 1, wherein the 8-iso prostanoid is selected from the group consisting of a compound having the following Formula III
Figure USRE039609-20070501-C00008
or a derivative thereof.
6. The method of claim 1, wherein the 8-iso prostanoid is selected from the group consisting of a compound having the following Formula IV
Figure USRE039609-20070501-C00009
or a derivative thereof.
7. The method of claim 2, wherein the 8-iso prostanoid is selected from the group consisting of a compound having the following Formula II
Figure USRE039609-20070501-C00010
or a derivative thereof.
8. The method of claim 2, wherein the 8-iso prostanoid is selected from the group consisting of a compound having the following Formula III
Figure USRE039609-20070501-C00011
or a derivative thereof.
9. The method of claim 2, wherein the 8-iso prostanoid is selected from the group consisting of a compound having the following Formula IV
Figure USRE039609-20070501-C00012
or a derivative thereof.
10. The method of claim 3, wherein 8-iso prostanoid is selected from the group consisting of a compound having the following Formula II
Figure USRE039609-20070501-C00013
or a derivative thereof.
11. The method of claim 3, wherein the 8-iso prostanoid is selected from the group consisting of a compound having the following Formula III
Figure USRE039609-20070501-C00014
or a derivative thereof.
12. The method of claim 3, wherein the 8-iso prostanoid is selected from the group consisting of a compound having the following Formula IV
Figure USRE039609-20070501-C00015
or a derivative thereof.
13. The method of claim 4, wherein the derivative is an ester derivative.
14. The method of claim 5, wherein the derivative is an ester derivative.
15. The method of claim 6, wherein the derivative is an ester derivative.
16. The method of claim 7, wherein the derivative is an ester derivative.
17. The method of claim 8, wherein the derivative is an ester derivative.
18. The method of claim 9, wherein the derivative is an ester derivative.
19. The method of claim 10, wherein the derivative is an ester derivative.
20. The method of claim 11, wherein the derivative is an ester derivative.
21. The method of claim 12, wherein the derivative is an ester derivative.
22. A method for decreasing intraocular pressure comprising administering a therapeutically effective amount of an 8-iso prostanoid having the following Formula I:
Figure USRE039609-20070501-C00016
where bond W is selected from the group consisting of a single covalent bond and a double covalent bond, bond X is selected from the group consisting of a single covalent bond and a double covalent bond and substituent Y is selected from the group consisting of a hydroxyl group having either α or β orientation relative to the five-membered ring and a keto function, to a patient in need of such treatment.
23. The method of claim 22 wherein the 8-iso prostanoid is administered topically.
24. The method of claim 22 wherein the 8-iso prostanoid is administered as a composition comprising between 0.005 to 1 percent 8 -iso prostanoid.
US10/073,838 1997-05-09 2002-02-11 8-iso-prostaglandins for glaucoma therapy Expired - Fee Related USRE39609E1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/073,838 USRE39609E1 (en) 1997-05-09 2002-02-11 8-iso-prostaglandins for glaucoma therapy

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US85380397A 1997-05-09 1997-05-09
US09/073,552 US6037368A (en) 1997-05-09 1998-05-06 8-iso- prostaglandins for glaucoma therapy
US10/073,838 USRE39609E1 (en) 1997-05-09 2002-02-11 8-iso-prostaglandins for glaucoma therapy

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/073,552 Reissue US6037368A (en) 1997-05-09 1998-05-06 8-iso- prostaglandins for glaucoma therapy

Publications (1)

Publication Number Publication Date
USRE39609E1 true USRE39609E1 (en) 2007-05-01

Family

ID=25316955

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/073,552 Ceased US6037368A (en) 1997-05-09 1998-05-06 8-iso- prostaglandins for glaucoma therapy
US10/073,838 Expired - Fee Related USRE39609E1 (en) 1997-05-09 2002-02-11 8-iso-prostaglandins for glaucoma therapy

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/073,552 Ceased US6037368A (en) 1997-05-09 1998-05-06 8-iso- prostaglandins for glaucoma therapy

Country Status (5)

Country Link
US (2) US6037368A (en)
EP (1) EP1007028A4 (en)
AU (1) AU725677B2 (en)
CA (1) CA2293325C (en)
WO (1) WO1998050024A1 (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1269785A (en) * 1997-09-09 2000-10-11 普罗克特和甘保尔公司 Aromatic C16-C20 substituted tetrahydro prostaglandius useful as EP agonists
TR200000673T2 (en) * 1997-09-09 2000-11-21 The Procter & Gamble Company Aromatic C16-C20-substituted tetrahydro prostaglandins useful as FP agonists.
BR9811774A (en) * 1997-09-09 2000-08-29 Procter & Gamble Aromatic tetrahydroprostaglandins substituted by c16-c20 useful as fp agonists
CN1350521A (en) 1999-03-05 2002-05-22 宝洁公司 C16 unsaturated FP-selective prostaglanding analogs
US6894175B1 (en) 1999-08-04 2005-05-17 The Procter & Gamble Company 2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
JP4000505B2 (en) 1999-12-01 2007-10-31 第一三共株式会社 Concomitant medications for treating glaucoma
US20020172693A1 (en) 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020037914A1 (en) * 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20050119262A1 (en) * 2003-08-21 2005-06-02 Pharmacia Corporation Method for preventing or treating an optic neuropathy with a cox-2 inhibitor and an intraocular pressure reducing agent
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
TW200927169A (en) * 2007-11-07 2009-07-01 Alcon Res Ltd Complement Clq inhibitors for the prevention and treatment of glaucoma
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8394826B2 (en) 2009-05-01 2013-03-12 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
EP2976080B1 (en) 2013-03-15 2019-12-25 Aerie Pharmaceuticals, Inc. Conjugates of isoquinoline compounds and prostaglandins
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
KR102568082B1 (en) 2016-08-31 2023-08-17 에어리 파마슈티컬즈, 인코포레이티드 ophthalmic composition
AU2018243687C1 (en) 2017-03-31 2020-12-24 Alcon Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
EP3849555A4 (en) 2018-09-14 2022-05-04 Aerie Pharmaceuticals, Inc. ARYL CYCLOPROPYL AMINO ISOCHINOLINYL AMIDE COMPOUNDS

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132847A (en) * 1977-07-22 1979-01-02 Pfizer Inc. 4-Pyrone prostaglandin antagonists
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5151444A (en) * 1987-09-18 1992-09-29 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
US5173507A (en) * 1988-07-18 1992-12-22 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5208256A (en) * 1990-05-22 1993-05-04 R-Tech Ueno, Ltd. Treatment of ocular hypertension with a synergistic combination for ocular administration
US5262437A (en) * 1990-12-10 1993-11-16 Allergan, Inc. Homo-prostaglandin derivatives as ocular hypotensives
WO1994011002A1 (en) * 1992-11-12 1994-05-26 Allergan, Inc. 8-epi prostaglandins
US5462968A (en) * 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5476872A (en) * 1993-10-18 1995-12-19 Allergan, Inc. 1,11-diesters of prostaglandin-F2α having a polar ester group at C-1
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5578618A (en) * 1988-09-06 1996-11-26 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4132847A (en) * 1977-07-22 1979-01-02 Pfizer Inc. 4-Pyrone prostaglandin antagonists
US4599353A (en) * 1982-05-03 1986-07-08 The Trustees Of Columbia University In The City Of New York Use of eicosanoids and their derivatives for treatment of ocular hypertension and glaucoma
US5151444A (en) * 1987-09-18 1992-09-29 K.K. Ueno Seiyaku Oyo Kenkyujo Ocular hypotensive agents
US5151444B1 (en) * 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
US5565492A (en) * 1988-07-18 1996-10-15 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5173507A (en) * 1988-07-18 1992-12-22 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5578618A (en) * 1988-09-06 1996-11-26 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5208256A (en) * 1990-05-22 1993-05-04 R-Tech Ueno, Ltd. Treatment of ocular hypertension with a synergistic combination for ocular administration
US5262437A (en) * 1990-12-10 1993-11-16 Allergan, Inc. Homo-prostaglandin derivatives as ocular hypotensives
WO1994011002A1 (en) * 1992-11-12 1994-05-26 Allergan, Inc. 8-epi prostaglandins
US6124353A (en) 1992-11-12 2000-09-26 Allergan Sales, Inc. Method of treating ocular hypertension with 8-epi prostaglandins
US5476872A (en) * 1993-10-18 1995-12-19 Allergan, Inc. 1,11-diesters of prostaglandin-F2α having a polar ester group at C-1
US5462968A (en) * 1994-01-19 1995-10-31 Allergan, Inc. EP2 -receptor agonists as agents for lowering intraocular pressure
US5631287A (en) * 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Podos et al., Mar. 15, 1998, Invest. Ophtalmol. Visual Sci. 39(4): S258, abstract 1178-B57, 1998. *
Wang et al., Mar. 15, 1997, Invest. Ophtalmol. Visual Sci. 38(4):S815, abstract 3795-B396. *

Also Published As

Publication number Publication date
CA2293325C (en) 2008-09-02
AU725677B2 (en) 2000-10-19
WO1998050024A1 (en) 1998-11-12
US6037368A (en) 2000-03-14
EP1007028A4 (en) 2002-06-05
AU7368698A (en) 1998-11-27
EP1007028A1 (en) 2000-06-14
CA2293325A1 (en) 1998-11-12

Similar Documents

Publication Publication Date Title
USRE39609E1 (en) 8-iso-prostaglandins for glaucoma therapy
US10045997B2 (en) Hypotensive lipid and timolol compositions and methods of using same
EP0569046B1 (en) Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US6376541B1 (en) Upregulation of endogenous prostaglandins to lower intraocular pressure
Kerstetter et al. Prostaglandin F2α-1-isopropylester lowers intraocular pressure without decreasing aqueous humor flow
AU2002312221A1 (en) Hypotensive lipid (prostaglandin derivatives) and timolol compositions and methods of using same
EP0979652B1 (en) Remedial composition for intraocular hypertension or glaucoma
US20020193441A1 (en) Prostanoid therapies for the treatment of glaucoma
EP1142576B1 (en) Drug compositions for the treatment of ocular hypertension or glaucoma
JPWO2000038689A1 (en) Pharmaceutical composition for treating ocular hypertension or glaucoma
AU2010202674B2 (en) Hypotensive lipid and timolol compositions and methods of using same
US4826812A (en) Antiglaucoma agent
EP0527748A1 (en) Use of prostaglandin F3 alpha as eyepiece hypotensif agent.
WO1994011002A1 (en) 8-epi prostaglandins
HK1070830B (en) Hypotensive lipid and timolol compositions and methods of using same
HK1024170B (en) Remedial composition for intraocular hypertension or glaucoma
AU2014201651A1 (en) Hypotensive lipid and timolol compositions and methods of using same
JPWO1999018969A1 (en) Composition for treating ocular hypertension or intraocular lens edema

Legal Events

Date Code Title Description
FPAY Fee payment

Year of fee payment: 8

REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees